BidaskClub Upgrades ANI Pharmaceuticals (ANIP) to “Buy”

BidaskClub upgraded shares of ANI Pharmaceuticals (NASDAQ:ANIP) from a hold rating to a buy rating in a research report sent to investors on Friday morning.

Other research analysts have also issued research reports about the company. TheStreet upgraded ANI Pharmaceuticals from a c+ rating to a b rating in a report on Thursday, November 16th. Zacks Investment Research upgraded ANI Pharmaceuticals from a hold rating to a buy rating and set a $71.00 price objective for the company in a research note on Tuesday, November 7th. ValuEngine upgraded ANI Pharmaceuticals from a hold rating to a buy rating in a research note on Saturday, November 4th. Finally, Canaccord Genuity reiterated a buy rating on shares of ANI Pharmaceuticals in a research note on Thursday, November 2nd. Three analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. The stock presently has an average rating of Buy and a consensus price target of $71.00.

Shares of ANI Pharmaceuticals (NASDAQ:ANIP) traded down $0.58 during mid-day trading on Friday, reaching $68.83. The company’s stock had a trading volume of 101,000 shares, compared to its average volume of 158,040. The company has a quick ratio of 2.39, a current ratio of 3.45 and a debt-to-equity ratio of 0.83. The stock has a market cap of $801.39, a price-to-earnings ratio of 109.25 and a beta of 2.90. ANI Pharmaceuticals has a 12 month low of $42.23 and a 12 month high of $74.70.

ANI Pharmaceuticals (NASDAQ:ANIP) last announced its quarterly earnings data on Thursday, November 2nd. The specialty pharmaceutical company reported $1.11 earnings per share for the quarter, beating analysts’ consensus estimates of $0.99 by $0.12. The company had revenue of $48.16 million for the quarter, compared to analyst estimates of $48.12 million. ANI Pharmaceuticals had a return on equity of 22.40% and a net margin of 4.45%. The firm’s revenue for the quarter was up 25.0% on a year-over-year basis. During the same quarter last year, the firm posted $1.09 EPS. equities research analysts predict that ANI Pharmaceuticals will post 3.59 earnings per share for the current year.

A number of hedge funds have recently made changes to their positions in ANIP. BNP Paribas Arbitrage SA grew its holdings in ANI Pharmaceuticals by 44.6% during the second quarter. BNP Paribas Arbitrage SA now owns 2,152 shares of the specialty pharmaceutical company’s stock worth $101,000 after acquiring an additional 664 shares during the period. SG Americas Securities LLC acquired a new position in ANI Pharmaceuticals during the third quarter worth $197,000. Stevens Capital Management LP acquired a new position in ANI Pharmaceuticals during the second quarter worth $207,000. Dynamic Technology Lab Private Ltd acquired a new position in ANI Pharmaceuticals during the second quarter worth $210,000. Finally, Violich Capital Management Inc. acquired a new position in ANI Pharmaceuticals during the third quarter worth $217,000. 55.05% of the stock is currently owned by hedge funds and other institutional investors.

WARNING: “BidaskClub Upgrades ANI Pharmaceuticals (ANIP) to “Buy”” was first reported by Community Financial News and is the property of of Community Financial News. If you are accessing this piece on another site, it was stolen and reposted in violation of U.S. and international copyright and trademark law. The original version of this piece can be read at https://www.com-unik.info/2018/01/09/bidaskclub-upgrades-ani-pharmaceuticals-anip-to-buy.html.

ANI Pharmaceuticals Company Profile

ANI Pharmaceuticals, Inc is an integrated specialty pharmaceutical company. The Company is engaged in developing, manufacturing and marketing branded and generic prescription pharmaceuticals. The Company focuses on areas, including controlled substances, anti-cancer (oncolytics), hormones and steroids, and complex formulations.

Receive News & Ratings for ANI Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ANI Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit